Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study.
Andrea BeccioliniSimone ParisiPatrizia Del MedicoAntonella FarinaElisa VisalliAldo Biagio Molica ColellaFederica LumettiRosalba CaccavalePalma ScolieriRomina AndraccoFrancesco GirelliElena BraviMatteo ColinaAlessandro VolpeAurora IannielloMaria Chiara DittoValeria NuceraVeronica FranchinaIlaria PlatèEleonora Di DonatoGiorgio AmatoCarlo SalvaraniSimone BernardiGianluca LucchiniFrancesco De LuciaFrancesco Molica ColellaDaniele SantilliNatalia MansuetoGiulio FerreroAntonio MarchettaEugenio ArrigoniRosario FotiGilda SandriVincenzo BruzzeseMarino ParoliEnrico FusaroAlarico ArianiPublished in: Biomedicines (2023)
Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA.